Ipsen continues its shopping spree with a $1B-plus deal for Exicure's next-gen oligonucleotides
Ipsen has been on a deal-making spree the last few weeks, shelling out more than a billion dollars in two separate deals to work on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
